2026-10-25
Guardian Pharmacy Services, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 27,087 +1.72%
S&P 7,401 +0.65%
GOLD $4,073 −1.00%
BTC $75,828 −0.15%
VIX 24.55 −12.88%
latest tape · as of 20:03 UTC
The Screen · Healthcare · Medical Care Facilities
Guardian Pharmacy Services, Inc.
GRDN · the NYSE · USD · Market cap $2.7B · 3,600 employees
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States.
Not yet scored39.87 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price39.87 USD at the 5 Nov 2026 close
- Our value readFair vs our fair value, as of 5 Nov 2026
- Our regime readMarkdown, as of 5 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.00)
- Last reviewed5 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $40.78 to $46.89, base estimate $40.78 (screen dated 2026-11-05).
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.00, read 2026-11-05
- Ethical screen not yet scored
Price39.87 USD
Fair value40.78
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-11Read Markdown42.38-5.9% to today ✓Markup gives way to Markdown with volume flow in agreement
2026-10-02Read Markup44.16-9.7% to today Distribution gives way to Markup after an 18% rise in 5 weeks
2026-08-31Read Distribution37.48+6.4% to today Accumulation gives way to Distribution after a 13% slide in 9 weeks
2026-07-02Read Accumulation43.09-7.5% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markdown label.
Guardian Pharmacy Services, Inc. holds its Markdown at $39.87. The statistical read favours the buyers, held for 7 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the buyers, held for 7 days |
| Price at the screen | $39.87 |
| Valuation | 40.86 trailing · 29.35 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 0.06 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 9.00% | Below 33% | Interest-bearing debt is just 9.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 40.53% | Below 49% | Money owed to the company is 40.5% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Guardian Pharmacy Services, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Guardian Pharmacy Services, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 9%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades above our $40.78 fair value estimate, 2.20% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 2.2% discount to the base estimate.
Third-party analyst targets: 7 covering, consensus Strong Buy. The average target sits +25% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $40.78, with a range of $40.78 to $46.89, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsCare home pharmacies trade above fair value
Every pill dispensed inside a US nursing home moves through specialised pharmacy networks that keep residents medicated on time. Guardian Pharmacy Services runs that operation, supplying tech-enabled dispensing and clinical support to long-term care facilities across the country.
Revenue is expanding at just 2% while the forward multiple sits at 29.8 times and margins remain stuck at 4%. The shares trade at 40.52 against a fair value of 38.44, so there is no margin of safety and the opportunity rating stays at none despite the clean ethical screen.
Return on equity reaches 27%, yet unknown competitive strength and thin growth leave the business exposed to reimbursement cuts and regulatory shifts in healthcare. Analysts see a median target of 47, but that does not change the lack of value on offer today.
Analysis, not advice.
| Forward P/E | 29.3xexpensive even after accounting for its growth |
| Trailing P/E | 40.9xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 1.03 |
| EPS, forward | 1.43 |
| Revenue growth | +2.2%slow but positive growth |
| Profit margin | 4.5%barely profitable |
| Return on equity | 30.4%an exceptional return on shareholder capital |
| FCF yield | 2.42% |
| Debt to equity | 0.15minimal debt: a conservative balance sheet |
| Current ratio | 1.65healthy short-term liquidity |
| Beta | 0.06barely tracks the market's swings |
| Short interest, float | 0.05% |
| 52-week range | 26.34 - 48.33 |
| Market cap | $2.7B |
| Employees | 3,600 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeGRDN trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-05
Markdown $42.09
+3.0% Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04
Markdown $40.87
+0.4% Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03
Markdown $40.69
+0.0% Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02
Markdown $40.69
+0.0% Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01
Markdown $40.69
+3.2% Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Markdown $39.44
+0.0% Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Markdown $39.44
+0.0% Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Markdown $39.44
+1.2% Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25
Markdown $38.98
-1.8% Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43.
2026-10-18
Markdown $39.68
-6.4% Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Guardian Pharmacy Services (GRDN) Stock May Trade At a Discount Following a 38% Climb Yahoo Finance · 13d ago
- Guardian Pharmacy Services, Inc. to Report Third Quarter 2026 Financial Results and Host Conference Call Yahoo Finance · 16d ago
- Zacks.com featured highlights include CNXN, ECG, GRDN, EXPD and PBF Yahoo Finance · 29 Sep 2026
- Bet on Winning DuPont Analysis & Pick 5 Top Stocks Yahoo Finance · 28 Sep 2026
- Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy Yahoo Finance · 1 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
BKDBrookdale Senior Living Inc.
MDPediatrix Medical Group, Inc.
AVAHAveanna Healthcare Holdings Inc.
ADUSAddus HomeCare Corporation
ACHCAcadia Healthcare Company, Inc.
SEMSelect Medical Holdings Corporation
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $35.65 | +17.6% | · | $1,176 | +17.6% |
| 2 months | $39.15 | +7.1% | · | $1,071 | +7.1% |
| 3 months | $33.27 | +26.1% | · | $1,261 | +26.1% |
| 6 months | $31.17 | +34.6% | · | $1,346 | +34.6% |
| 1 year | $20.63 | +103.3% | · | $2,033 | +103.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever GRDN does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.